Home / Products / Genome-edited Cells / TNF Knockout THP-1 Cell Line

TNF Knockout THP-1 Cell Line

Cat. No. ARG0827
Product Type:

Genome-edited Cells

Tissue Source:

Blood (peripheral blood)

In stock
Request a Quote

Short Description 🔒

The TNF Knockout THP-1 Cell Line is a CRISPR/Cas9-edited human monocytic leukemia cell line lacking tumor necrosis factor (TNF) expression. Derived from THP-1 cells??a model of monocyte-macrophage differentiation??this cell line eliminates autocrine/paracrine TNF signaling, disrupting key inflammatory and cell death pathways mediated by TNFR1, NF-??B, and caspase-8. This loss-of-function model is designed for mechanistic studies of TNF-dependent signaling, cytokine network analysis, and drug screening for TNF inhibitors. Typical applications include ELISA, qPCR, Western blotting, flow cytometry, and functional macrophage assays, enabling precise dissection of inflammatory responses in a well-characterized human cellular system.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Genome-edited Cells
Tissue Source:
Blood (peripheral blood)
Disease:
Acute monoblastic leukemia
Age:
1 year
Sex of Donor:
Male
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice

Cell Engineering Information

Host Cell:
THP-1
Gene Name:
TNF
Gene Identifier:
NCBI Gene ID 7124
Gene Species:
Homo sapiens (Human)

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Pathogens:
Cells tested negative for HIV-1, HBV, and HCV.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The TNF Knockout THP-1 Cell Line is a CRISPR/Cas9-edited human monocytic leukemia cell line in which the gene encoding tumor necrosis factor (TNF) has been disrupted. This loss-of-function model is generated using CRISPR/Cas9-mediated gene editing to abrogate TNF expression, providing a defined platform for dissecting TNF-dependent signaling mechanisms and inflammatory responses. The cell line is derived from the THP-1 host cell, a widely used model for monocyte-macrophage biology.

THP-1 cells were originally isolated from the peripheral blood of a 1-year-old male patient with acute monocytic leukemia and retain many characteristics of native monocytes. Upon stimulation with phorbol esters such as PMA, they differentiate into macrophage-like cells, recapitulating key features of macrophage maturation, including enhanced phagocytic capacity and cytokine release. This property makes THP-1 an indispensable tool for studying monocyte differentiation, innate immune activation, and the molecular circuitry governing inflammatory phenotypes in a genetically tractable human cell line.

TNF is a master pro-inflammatory cytokine that signals primarily through TNF receptor 1 (TNFR1). Ligand binding triggers the recruitment of adaptor proteins TRADD, TRAF2, and RIPK1, which orchestrate the activation of the IKK complex, leading to I??B?? phosphorylation and subsequent nuclear translocation of the NF-??B transcription factor. Parallel signaling through the MAPK cascade??including JNK and p38??further amplifies inflammatory gene expression programs. Under certain conditions, TNFR1 can also assemble a cytosolic death-inducing complex with FADD and caspase-8, initiating extrinsic apoptosis. TNF thereby controls the expression of multiple downstream targets such as IL-6, IL-8, and COX-2, and its activity is modulated by upstream regulators including LPS/TLR4 engagement, IL-1??, and transcription factors NF-??B and AP-1.

In the THP-1 background, TNF knockout eliminates both autocrine and paracrine TNF signaling, profoundly altering the cell’s inflammatory repertoire. Because THP-1 macrophages produce significant amounts of TNF during lipopolysaccharide (LPS) stimulation, ablation of the cytokine blocks feed-forward activation of NF-??B and MAPK pathways, resulting in diminished secretion of pro-inflammatory mediators and an attenuated immune response. Moreover, loss of TNF disrupts the balance between survival signaling and apoptosis induction, sensitizing the cells to death stimuli that normally engage the TNFR1 pathway. This model thus uniquely illuminates the dual role of TNF in sustaining chronic inflammation and governing cell fate decisions within a macrophage-like context.

Researchers can employ the TNF Knockout THP-1 Cell Line in a wide array of functional studies. It is particularly suited for dissecting the TNF/TNFR1 axis using techniques such as ELISA-based cytokine profiling, quantitative PCR analysis of NF-??B target genes, and Western blotting for phospho-p65 and I??B?? degradation kinetics. The line is also valuable in drug discovery programs screening for TNF inhibitors, as well as in assays measuring apoptosis via flow cytometry (e.g., Annexin V staining) and macrophage differentiation after PMA treatment. Additional applications include phagocytosis assays to assess the role of TNF in innate immune effector functions and NF-??B luciferase reporter studies to quantify pathway activity. For additional information, please contact Ascent Research.